BioLineRx Ltd. Research And Development Expense

• BioLineRx Ltd. showed a decrease of -11.5% in Research And Development Expense from 2024 to 2025.
• This data is from BioLineRx Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), BioLineRx Ltd.'s Research And Development Expense has declined by 29.6%.
• Historical annual values: Fiscal year 2025: $8.09 million | Fiscal year 2024: $9.15 million | Fiscal year 2023: $12.52 million | Fiscal year 2022: $17.63 million | Fiscal year 2021: $19.47 million | Fiscal year 2020: $18.17 million | Fiscal year 2019: $23.44 million | Fiscal year 2018: $19.81 million | Fiscal year 2017: $19.51 million | Fiscal year 2016: $11.18 million | Fiscal year 2015: $11.49 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026